Sex Differences in Pharmacokinetics and Pharmacodynamics

Annual Review of Pharmacology and Toxicology

Volumn 44, Issue , 2004, Pages 499-523

  Gandhi, Monica ^a   Aweeka, Francesca ^b   Greenblatt, Ruth M ^a   Blaschke, Terrence F ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome P450; Drug disposition; Gender differences; HIV infection; Metabolism

Indexed keywords

ANTIRETROVIRUS AGENT; CLOFIBRATE; CYTOCHROME P450; DEXAMETHASONE; ERYTHROMYCIN; MIDAZOLAM; NEVIRAPINE; PHENOBARBITAL; RNA DIRECTED DNA POLYMERASE INHIBITOR; VERAPAMIL;

BODY WEIGHT; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SEX DIFFERENCE; STOMACH EMPTYING; TOXICITY TESTING;

ANTI-RETROVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; SEX FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1342302371     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.44.101802.121453     Document Type: Review

References (173)

1. US Dep. Health Hum. Serv. Health Serv., Natl. Inst. Health. 1999. Agenda for Research on Women's Health for the 21st Century: A Report of the Task Force on the NIH Women's Health Research
2. US Gen. Account. Office (GAO). 2001. Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement. (http://www.gao.gov/new.items/d01754.pdf)
3. Martinez MN, Amidon GL. 2002. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 42:620-43
4. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, et al. 1990. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res. 7:756-61
5. Lindahl A, Ungell AL, Knutson L, Lennemas H. 1997. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14:497-502
6. Collen MJ, Sheridan MJ. 1993. Gastric ulcers differ from duodenal ulcers. Evaluation of basal acid output. Dig. Dis. Sci. 38:2281-86
7. Roland B, Grijalva CV. 1991. Gastric mucosal damage induced by lateral hypothalamic lesions in female rats: influence of age and ovariectomy. Behav. Neural. Biol. 55:166-78
8. Collen MJ, Abdulian JD, Chen YK. 1994. Age does not affect basal gastric acid secretion in normal subjects or in patients with acid-peptic disease. Am. J. Gastroenterol. 89:712-16
9. Hutson WR, Roehrkasse RL, Wald A. 1989. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 96:11-17
10. Singer AJ, Brandt LJ. 1991. Pathophysiology of the gastrointestinal tract during pregnancy. Am. J. Gastroenterol. 86:1695-712
11. Wu CL, Hung CR, Chang FY, Pau KY, Wang JL, Wang PS. 2002. Involvement of cholecystokinin receptor in the inhibition of gastric emptying by oxytocin in male rats. Pflugers. Arch. 445:187-93
12. Coskun T, Sevinc A, Tevetoglu I, Alican I, Kurtel H, Yegen BC. 1995. Delayed gastric emptying in conscious male rats following chronic estrogen and progesterone treatment. Res. Exp. Med. 195:49-54
13. Liu CY, Chen LB, Liu PY, Xie DP, Wang PS. 2002. Effects of progesterone on gastric emptying and intestinal transit in malerats. World J. Gastroenterol. 8:338-41
14. Chen TS, Doong ML, Chang FY, Lee SD, Wang PS. 1995. Effects of sex steroid hormones on gastric emptying and gastrointestinal transit in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 268:G171-76
15. Sadik R, Abrahamsson H, Stotzer PO. 2003. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J. Gastroenterol. 38:36-42
16. Mearadji B, Penning C, Vu MK, van der Schaar PJ, van Petersen AS, et al. 2001. Influence of gender on proximal gastric motor and sensory function. Am. J. Gastroenterol. 96:2066-73
17. Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, et al. 2001. Gender differences in pharmacokinetics of alcohol. Alcohol Clin. Exp. Res. 25:502-7
18. Naslund E, Bogefors J, Gryback P, Jacobsson H, Hellstrom PM. 2000. Gastric emptying: comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer assessment techniques. Scand J. Gastroenterol. 35:375-79
19. Bennink R, Peeters M, Van den Maegdenbergh V, Geypens B, Rutgeerts P, et al. 1999. Evaluation of small-bowel transit for solid and liquid test meal in healthy men and women. Eur. J. Nucl. Med. 26:1560-66
20. Caballero-Plasencia AM, Valenzuela-Barranco M, Martin-Ruiz JL, Herrerias-Gutierrez JM, Esteban-Carrettero JM. 1999. Are there changes in gastric emptying during the menstrual cycle? Scand J. Gastroenterol. 34:772-76
21. Horowitz M, Maddern GJ, Chatterton BE, Collins PJ, Petrucco OM, et al. 1985. The normal menstrual cycle has no effect on gastric emptying. Br. J. Obstet. Gynaecol. 92:743-46
22. Pastino GM, Flynn EJ, Sultatos LG. 2000. Genetic polymorphisms in ethanol metabolism: issues and goals for physiologically based pharmacokinetic modeling. Drug Chem. Toxicol. 23:179-201
23. Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. 1990. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N. Engl. J. Med. 322:95-99
24. Lee SF, Chen ZY, Fong WP. 2001. Gender difference in enzymes related with alcohol consumption in hamster, an avid consumer of alcohol. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 129: 285-93
25. Aasmoe L, Aarbakke J. 1999. Sex-dependent induction of alcohol dehydrogenase activity in rats. Biochem. Pharmacol. 57:1067-72
26. Johnson TN, Tanner MS, Tucker GT. 2000. A comparison of the ontogeny of enterocytic and hepatic cytochromes P450 3A in the rat. Biochem. Pharmacol. 60:1601-10
27. Kolars JC, Schmiedlin-Ren P, Dobbins WO 3rd, Schuetz J, Wrighton SA, Watkins PB. 1992. Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102:1186-98
28. Kim R, Leake B, Choo E, Dresser GK, Kubba SV, et al. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmcol. Ther. 70:189-99
29. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, et al. 2001. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383-84
30. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. 2000. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin. Pharmacol. Ther. 68:286-92
31. Mesnil F, Mentre F, Dubruc C, Thenot JP, Mallet 1998. Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. J. Pharmacokinet. Biopharm. 26:133-61
32. Woodhead JC, Drulis JM, Nelson SE, Janghorbani M, Fomon SJ. 1991. Gender-related differences in iron absorption by preadolescent children. Pediatr. Res. 29:435-39
33. Miaskiewicz SL, Shively CA, Vesell ES. 1982. Sex differences in absorption kinetics of sodium salicylate. Clin. Pharmacol. Ther. 31:30-37
34. Aarons L, Hopkins K, Rowland M, Brossel S, Thiercelin JF. 1989. Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. Pharm. Res. 6:660-66
35. Montgomery PR, Berger LG, Mitenko PA, Sitar DS. 1986. Salicylate metabolism: effects of age and sex in adults. Clin. Pharmacol. Ther. 39:571-76
36. Takaya T, Takeyama K, Miura M, Takiguchi M. 2001. Influence of body fat on the onset of vecuronium induced neuromuscular blockade. Tokai J. Exp. Clin. Med. 26:107-11
37. Xue FS, An G, Liao X, Zou Q, Luo LK. 1998. The pharmacokinetics of vecuronium in male and female patients. Anesth. Analg. 86:1322-27
38. Semple P, Hope DA, Clyburn P, Rodbert A. 1994. Relative potency of vecuronium in male and female patients in Britain and Australia. Br. J. Anaesth. 72:190-94
39. Houghton IT, Aun CS, Oh TE. 1992. Vecuronium: an anthropometric comparison. Anaesthesia 47:741-46
40. Xue FS, Tong SY, Liao X, Liu JH, An G, Luo LK. 1997. Dose-response and time course of effect of rocuronium in male and female anesthetized patients. Anesth. Analg. 85:667-71
41. Ochs HR, Greenblatt DJ, Divoll M, Abernethy DR, Feyerabend H, Dengler HJ. 1981. Diazepam kinetics in relation to age and sex. Pharmacology 23:24-30
42. Greenblatt DJ, Allen MD, Harmatz JS, Shader RI. 1980. Diazepam disposition determinants. Clin. Pharmacol. Ther. 27: 301-12
43. Carcas AJ, Guerra P, Frias J, Soto A, Femandez-Aijon A, et al. 2001. Gender differences in the disposition of metronidazole. Int. J. Clin. Pharmacol. Ther. 39:213-18
44. Sowinski KM, Abel SR, Clark WR, Mueller BA. 1999. Effect of gender on the pharmacokinetics of ofloxacin. Pharmacotherapy 19:442-46
45. Bertino JS Jr, Nafziger AN. 1996. Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers. Antimicrob. Agents Chemother. 40:789-91
46. Magee MH, Blum RA, Lates CD, Jusko WJ. 2001. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J. Clin. Pharmacol. 41: 1180-94
47. Succari M, Foglietti MJ, Percheron F. 1990. Microheterogeneity of alpha 1-acid glycoprotein: variation during the menstrual cycle in healthy women, and profile in women receiving estrogen-progestogen treatment. Clin. Chim. Acta 187:235-41
48. Walle UK, Fagan TC, Topmiller MJ, Conradi EC, Walle T. 1994. The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers. Br. J. Clin. Pharmacol. 37:21-25
49. Tuck CH, Holleran S, Berglund L. 1997. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phae reactants in postmenopausal women. Arterioscler Thromb. Vasc. Biol. 17:1822-29
50. Brinkman-Van der Linden CM, Havenaar EC, Van Ommen CR, Van Kamp GJ, Gooren LJ, et al. 1996. Oral estrogen treatment induces a decrease in expression of sialyl Lewis x on alpha 1-acid glycoprotein in females and male-to-female transsexuals. Glycobiology 6:407-12
51. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, et al. 2003. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 67:361-66
52. Haram K, Augensen K, Elsayed S. 1983. Serum protein pattern in normal pregnancy with special reference to acute-phase reactants. Br. J. Obstet. Gynaecol. 90:139-45
53. Aquirre C, Rodriguez-Sasiain JM, Navajas P, Calvo R. 1988. Plasma protein binding of penbutolol in pregnancy. Eur. J. Drug Metab. Pharmacokinet. 13:23-26
54. Wood M, Wood AJ. 1981. Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin. Pharmacol. Ther. 29:522-26
55. Chu CY, Singla VP, Wang HP, Sweet B, Lai LT. 1981. Plasma alpha 1-acid glycoprotein levels in pregnancy. Clin. Chim. Acta 112:235-40
56. Notarianni LJ. 1990. Plasma protein binding of drugs in pregnancy and in neonates. Clin. Pharmacokinet. 18:20-36
57. Hill MD, Abramson FP. 1988. The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin. Pharmacokinet. 14:156-70
58. Perucca E, Crema A. 1982. Plasma protein binding of drugs in pregnancy. Clin. Pharmacokinet. 7:336-52
59. Cristofol C, Navarro M, Franquelo C, Valladares JE, Arboix M. 1998. Sex differences in the disposition of albendazole metabolites in sheep. Vet. Parasitol. 78:223-31
60. Nock B, Cicero TJ, Wich M. 1998. Chronic exposure to morphine decreases physiologically active corticosterone in both male and female rats but by different mechanisms. J. Pharmacol. Exp. Ther. 286:875-82
61. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, et al. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491-502
62. Weinshilboum R. 2003. Inheritance and drug response. N. Engl. J. Med. 348:529-37
63. Kashuba A, Nafziger A. 1998. Physiological changes during the menstrual cycle and their effects on the pharmacokinetic and pharmacodynamics of drugs. Clin. Pharmacokinet. 34:203-18
64. Finnstrom N, Ask B, Dahl ML, Gadd M, Rane A. 2002. Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes. Pharmacogenomics J. 2:111-16
65. Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R. 2001. Gender difference in ifosfamide metabolism by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 26:193-200
66. Hunt CM, Westerkam WR, Stave GM. 1992. Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol. 44:275-83
67. Miura T, Komori M, Iwasaki M, Kurozumi K, Ohta K, et al. 1988. Sex-related difference in oxidative metabolism of testosterone and erythromycin by hamster liver microsomes. FEBSLett. 231:183-86
68. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, et al. 1990. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin. Pharmacol. Ther. 48:365-74
69. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-23
70. George J, Byth K, Farrell GC. 1995. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem. Pharmacol. 50:727-30
71. Anakk S, Ku CY, Vore M, Strobel HW. 2003. Insights into gender bias: rat cytochrome P450 3A9. J. Pharmacol. Exp. Ther. 305:703-9
72. Kalsotra A, Anakk S, Boehme CL, Strobel HW. 2002. Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab. Dispos. 30:1022-28
73. Waskiewicz MJ, Choudhuri S, Vanderbeck SM, Zhang XJ, Thomas PE. 1995. Induction of "male-specific" cytochrome P450 isozymes in female rats by oxandrolone. Drug Metab. Dispos. 23:1291-96
74. Sakuma T, Endo Y, Mashino M, Kuroiwa M, Ohara A, et al. 2002. Regulation of the expression of two female-predominant CYP3A mRNAs (CYP3A-41 and CYP3A44) in mouse liver by sex and growth hormones. Arch. Biochem. Biophys. 404:234-42
75. Choudhuri S, Zhang XJ, Waskiewicz MJ, Thomas PE. 1995. Differential regulation of cytochrome P450 3A1 and P450 3A2 in rat liver following dexamethasone treatment. J. Biochem. Toxicol. 10:299-307
76. Larsen MC, Brake PB, Parmar D, Jefcoate CR. 1994. The induction of five rat hepatic P450 cytochromes by phenobarbital and similarly acting compounds is regulated by a sexually dimorphic, dietary-dependent endocrine factor that is highly strain specific. Arch. Biochem. Biophys. 315:24-34
77. Sundseth SS, Waxman DJ. 1992. Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. J. Biol. Chem. 267:3915-21
78. Skaanild MT, Friis C. 1999. Cytochrome P450 sex differences in minipigs and conventional pigs. Pharmacol. Toxicol. 85:174-80
79. Austin KL, Mather LE, Philpot CR, McDonald PJ. 1980. Intersubject and dose-related variability after intravenous administration of erythromycin. Br. J. Clin. Pharmacol. 10:273-79
80. Chiou WL, Jeong HY, Wu TC, Ma C. 2001. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin. Pharmacol. Ther. 70:305-10
81. Rivory LP, Watkins PB. 2001. Erythromycin breath test. Clin. Pharmacol. Ther. 70:395-99
82. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, et al. 1992. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin. Pharmacol. Ther. 52:265-73
83. Hunt CM, Westerkam WR, Stave GM, Wilson JA. 1992. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech. Ageing Dev. 64:189-99
84. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, et al. 1994. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 271:557-66
85. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, et al. 1994. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271:549-56
86. Kashuba AD, Bertino JS Jr, Rocci ML Jr, Kulawy RW, Beck DJ, et al. 1998. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin. Pharmacol. Ther. 64:269-77
87. Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, et al. 1999. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin. Pharmacol. Ther. 66:224-31
88. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, et al. 1984. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61:27-35
89. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, et al. 1995. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther. 57:16-24
90. Holazo AA, Winkler MB, Patel IH. 1988. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J. Clin. Pharmacol. 28:1040-45
91. Nishiyama T, Matsukawa T, Hanaoka K. 1998. The effects of age and gender on the optimal premedication dose of intramuscular midazolam. Anesth. Analg. 86:1103-8
92. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, et al. 1998. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64:133-43
93. Greenblatt DJ, Locniskar A, Scavone JM, Blyden GT, Ochs HR, et al. 1986. Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. Anesth. Analg. 65:176-80
94. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, et al. 1994. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22:947-55
95. Lampen A, Christians U, Bader A, Hackbarth I, Sewing KF. 1996. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology. 52:159-68
96. Christians U, Bleck JS, Lampen A, Bader A, Thiesemann C, et al. 1996. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem? Transplant. Proc. 28:2159-61
97. Krecic-Shepard M, Barnas C, Slimko J, Jones M, Schwartz J. 2000. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J. Clin. Pharmacol. 40:219-30
98. Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, et al. 2003. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin. Pharmacol. Ther. 73:31-40
99. Sawicki W. 2002. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. Eur. J. Pharm. Biopharm. 53:29-35
100. Sasaki M, Tateishi T, Ebihara A. 1993. The effects of age and gender on the stereoselective pharmacokinetics of verapamil. Clin. Pharmacol. Ther. 54:278-85
101. Cummins CL, Wu CY, Benet LZ. 2002. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 72:474-89
102. Schuetz EG, Furuya KN, Schuetz JD. 1995. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275:1011-18
103. Meibohm B, Beierle I, Derendorf H. 2002. How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 41:329-42
104. Morris ME, Lee HJ, Predko LM. 2003. Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol. Rev. 55:229-40
105. Prior TI, Baker GB. 2003. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry Neurosci. 28:99-112
106. Lam LC, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VK, et al. 2001. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 34:238-41
107. Tanaka E, Kurata N, Yasuhara H. 2003. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J. Clin. Pharm. Ther. 28:157-65
108. Laine K, Tybring G, Bertilsson L. 2000. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin. Pharmacol. Ther. 68:151-59
109. Kharasch ED, Mautz D, Senn T, Lentz G, Cox K. 1999. Menstrual cycle variability in midazolam pharmacokinetics. J. Clin. Pharmacol. 39:275-80
110. Shah AK, Laboy-Goral L, Scott N, Morse T, Apseloff G. 2001. Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. J. Clin. Pharmacol. 41:1339-44
111. McCune JS, Lindley C, Decker JL, Williamson KM, Meadowcroft AM, et al. 2001. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J. Clin. Pharmacol. 41:723-31
112. Fleishaker JC, Pearson LK, Pearson PG, Wienkers LC, Hopkins NK, et al. 1999. Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. J. Clin. Pharmacol. 39:260-67
113. Gorski JC, Wang Z, Haehner-Daniels BD, Wrighton SA, Hall SD. 2000. The effect of hormone replacement therapy on CYP3A activity. Clin. Pharmacol. Ther. 68:412-17
114. Harris RZ, Tsunoda SM, Mroczkowski P, Wong H, Benet LZ. 1996. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin. Pharmacol. Ther. 59:429-35
115. Lemmens HJ, Burm AG, Hennis PJ, Gladines MP, Bovill JG. 1990. Influence of age on the pharmacokinetics of alfentanil. Gender dependence. Clin. Pharmacokinet. 19:416-22
116. Rubio A, Cox C. 1991. Sex, age and alfentanil pharmacokinetics. Clin. Pharmacokinet. 21:81-82
117. Hermann R, Ferron GM, Erb K, Knebel N, Ruus P, et al. 2003. Effects of age and sex on the disposition of retigabine. Clin. Pharmacol. Ther. 73:61-70
118. Schuttler J, Ihmsen H. 2000. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 92:727-38
119. Sowinski KM, Abel SR, Clark WR, Mueller BA. 1999. Effect of gender on the pharmacokinetics of ofloxacin. Pharmacotherapy 19:442-46
120. Cerrutti JA, Quaglia NB, Brandoni A, Torres AM. 2002. Effects of gender on the pharmacokinetics of drugs secreted by the renal organic anions transport systems in the rat. Pharmacol. Res. 45:107-12
121. Cerrutti JA, Brandoni A, Quaglia NB, Torres AM. 2002. Sex differences in p-aminohippuric acid transport in rat kidney: role of membrane fluidity and expression of OAT1. Mol. Cell. Biochem. 233:175-79
122. Kudo N, Suzuki E, Katakura M, Ohmori K, Noshiro R, et al. 2001. Comparison of the elimination between perfluorinated fatty acids with different carbon chain length in rats. Chem. Biol. Interact. 134:203-16
123. Reyes JL, Melendez E, Alegria A, Jaramillo-Juarez F. 1998. Influence of sex differences on the renal secretion of organic anions. Endocrinology 139:1581-87
124. Vanden Heuvel JP, Davis JW 2nd, Sommers R, Peterson RE. 1992. Renal excretion of perfluorooctanoic acid in male rats: inhibitory effect of testosterone. J. Biochem. Toxicol. 7:31-36
125. Gaudry SE, Sitar DS, Smyth DD, McKenzie JK, Aoki FY. 1993. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin. Pharmacol. Ther. 54:23-27
126. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E Jr, et al. 1993. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 54:402-14
127. Gupta SK, Atkinson L, Tu T, Longstreth JA. 1995. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. Br. J. Clin. Pharmacol. 40:325-31
128. Craft RM. 2003. Sex differences in drug-and non-drug-induced analgesia. Life Sci. 72:2675-88
129. Unruh AM. 1996. Gender variations in clinical pain experience. Pain 65:123-67
130. Unruh AM, Ritchie J, Merskey H. 1999. Does gender affect appraisal of pain and pain coping strategies? Clin. J. Pain 15:31-40
131. Berkley K. 1997. Sex differences in pain. Behav. Brain Sci. 20:371-80
132. Fillingim R. 2000. Sex, gender, and pain: women and men really are different. Curr. Rev. Pain 4:24-30
133. Craft RM. 2003. Sex differences in opioid analgesia: "from mouse to man." Clin. J. Pain 19:175-86
134. Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, et al. 2000. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology 93:1245-54; discussion 6A
135. Gordon NC, Gear RW, Heller PH, Paul S, Miaskowski C, Levine JD. 1995. Enhancement of morphine analgesia by the GABA-B agonist baclofen. Neuroscience 69:345-49
136. Craft RM, Bemal SA. 2001. Sex differences in opioid antinociception: kappa and mixed action agonists. Drug Alcohol Depend. 63:215-28
137. a. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, et al. 2003. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin. Pharmacol. Ther. 74:102-12
138. Craft RM, Millholland RB. 1998. Sex differences in cocaine- and nicotine-induced antinociception in the rat. Brain Res. 809:137-40
139. Carstens E, Anderson KA, Simons CT, Carstens MI, Jinks SL. 2001. Analgesia induced by chronic nicotine infusion in rats: differences by gender and pain test. Psychopharmacology 157:40-45
140. Jamner LD, Girdler SS, Shapiro D, Jarvik ME. 1998. Pain inhibition, nicotine, and gender. Exp. Clin. Psychopharmacol. 6:96-106
141. Kavaliers M, Choleris E. 1997. Sex differences in N-methyl-D-aspartate involvement in kappa opioid and non-opioid predator-induced analgesia in mice. Brain Res. 768:30-36
142. Traustadottir T, Bosch PR, Matt KS. 2003. Gender differences in cardiovascular and hypothalamic-pituitary-adrenal axis responses to psychological stress in healthy older adult men and women. Stress 6:133-40
143. Wilson MA, Biscardi R. 1994. Sex differences in GABA/benzodiazepine receptor changes and corticosteroine release after acute stress in rats. Exp. Brain Res. 101:297-306
144. Pleym H, Spigset O, Kharasch ED, Dale O. 2003. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol. Scand. 47:241-59
145. Xue FS, Liao X, Liu JH, Tong SY, Zhang YM, et al. 1998. Dose-response curve and time-course of effect of vecuronium in male and female patients. Br. J. Anaesth. 80:720-24
146. Apfelbaum JL, Grasela TH, Hug CC Jr, McLeskey CH, Nahrwold ML, et al. 1993. The initial clinical experience of 1819 physicians in maintaining anesthesia with propofol: characteristics associated with prolonged time to awakening. Anesth. Analg. 77:S10-14
147. Vuyk J, Oostwouder CJ, Vletter AA, Burm AG, Bovill JG. 2001. Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. Br. J. Anaesth. 86:183-88
148. Gan TJ, Glass PS, Sigl J, Sebel P, Payne F, et al. 1999. Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men. Anesthesiology 90:1283-87
149. Palva ES. 1985. Gender-related differences in diazepam effects on performance. Med. Biol. 63:92-95
150. Yonkers KA, Brawman-Mintzer O. 2002. The pharmacologic treatment of depression: is gender a critical factor? J. Clin. Psychiatry 63:610-15
151. Yonkers KA, Kando JC, Cole JO, Blumenthal S. 1992. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry 149:587-95
152. Yonkers KA, Harrison W. 1993. The inclusion of women in psychopharmacologic trials. J. Clin. Psychopharmacol. 13:380-82
153. Chouinard G, Annable L. 1982. Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology 76:13-19
154. Chouinard G, Annable L, Steinberg S. 1986. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J. Clin. Psychopharmacol. 6:21-26
155. Frackiewicz EJ, Sramek JJ, Cutler NR. 2000. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann. Pharmacother. 34:80-88
156. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, et al. 1999. The relationship between ritonavir plasma levels and side effects: implications for therapeutic drug monitoring. AIDS 13:2083-89
157. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, et al. 2002. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 16:737-45
158. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, et al. 2000. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J. Acquir. Immune Defic. Syndr. 23:236-45
159. Lucas GM, Chaisson RE, Moore RD. 1999. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131:81-87
160. Moore RD, Fortgang I, Keruly J, Chaisson RE. 1996. Adverse events from drug therapy for human immunodeficiency virus disease. Am. J. Med. 101:34-40
161. Currier J, Spino C, Grimes J, Wofsy C, Katzenstein D, et al. 2000. Differences between women and men in adverse events and CD4+ responses to nucleoside analog therapy for HIV infection. J. Acquir. Immune Defic. Syndr. 24:316-24
162. Anderson P, Kakuda T, Kawle S, Fletcher C. 2003. Sex differences in zidovudine (ZDV) and lamivudine (3TC) triphosphate concentrations in HIV-infected patients. 4th Int. Worksh. Clin. Pharmacol. HIV Ther., March 27-29, Cannes (Abstr. 53 P 7.2)
163. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick HJ Jr, et al. 2001. Sex differences in nevirapine rash. Clin. Infect. Dis. 32:124-29
164. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. 2002. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 16:1566-68
165. Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, et al. 2001. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 15:1579-80
166. La Porte C, Burger D, Gyssens I, Sprenger H, Koopmans P. 2003. Gender differences in nevirapine pharmacokinetics, fact or fiction? 4th Int. Worksh. Clin. Pharmacol. HIV Ther., March 27-29, Cannes (Abstr. 3.1)
167. Moore AL, Sabin CA, Johnson MA, Phillips AN. 2002. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J. Acquir. Immune Defic. Syndr. 29:197-202
168. Moore AL, Mocroft A, Madge S, Devereux H, Wilson D, et al. 2001. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J. Acquir. Immune Defic. Syndr. 26:159-63
169. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, et al. 2003. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J. Acquir. Immune Defic. Syndr. 32:452-61
170. Perez-Hoyos S, del Amo J, Muga R, del Romero J, Garcia de Olalla P, et al. 2003. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 17:353-59
171. Currier JS, Spino C, Grimes J, Wofs CB, Katzenstein DA, et al. 2000. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J. Acquir. Immune Defic. Syndr. 24:316-24
172. Pardo M, Ruiz M, Gimeno A, Navarro L, Garcia A, et al. 2002. Gender bias in clinical trials of AIDS drugs. Presented at XIV Int. AIDS Conf., Barcelona. Abstr. No. WePeB5964
173. Rademaker M. 2001. Do women have more adverse drug reactions? Am. J Clin. Dermatol. 2:349-51